Sequire Cannabis & Psychedelic Conference Announces Industry Speakers for 4/20 Event

Westlake Village, California, UNITED STATES


LOS ANGELES, April 19, 2022 (GLOBE NEWSWIRE) -- SRAX, Inc. (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, has announced the speakers for the Sequire Cannabis & Psychedelic Conference on April 20th, 2022.

Register Here: https://cannabis-conference22.mysequire.com/

Nearly nine million active small-cap investors have been invited to the event, which will feature over 30 Cannabis & Psychedelic companies hosting 25 minute presentations, as well as 1:1 meetings with investors, and keynotes highlighting notable names in these spaces.

Here are the panels and featured speakers:

Exploring the Value and Application of Botanical and Synthetic Formulations in Psychedelic Medicine
In this conversation, Dr. Matt Johnson, Joel Stanley, and David Drapkin discuss clinical research on psychedelic compounds, specifically differentiating the development, usage, and value of botanical formulations and synthetic or single molecule formulations. They will explore the value of botanic formulations and touch on the legal and pharmaceutical landscape in psychedelics today. Dr. Johnson explains the potential of these compounds and what it means for the treatment of mental disorders including addiction, trauma, depression, PTSD, ADHD, and anxiety.

Building An Industry Worthy of The Plant
During this conversation Steve DeAngelo and Andrew DeAngelo share insider knowledge about the current cannabis landscape, latest developments in the industry, and what to expect in the near future as cannabis legalization expands across the nation.

Debt Capital For Everyone with James Dworkin

Hear from James Dworkin, Managing Director of Seaport Global Securities, on the state of the cannabis debt, equity, and M&A markets and how everyone can access them. Seaport Global is a privately held capital markets firm specializing in global credit sales, trading and research, and investment banking. Through strong, long-standing relationships across sectors and a powerful credit distribution network, Seaport gives institutional clients the most informed and comprehensive view of the specialized secondary market.

Event: 2022 Sequire Cannabis & Psychedelic Conference
Date: Wednesday, April 20th, 2022
Time: 9:00am ET - 4:00pm ET
Register Here: https://cannabis-conference22.mysequire.com/
1:1 Meetings: Sign up for 1:1 meetings with Sequire Clients for free!

“The whole team is really excited to host these incredible companies and speakers for our 2nd Annual Sequire Cannabis & Psychedelic Conference. We have some returning legends, like Steve DeAngelo, as well as many new experts, sharing their insights on the Cannabis and Psychedelic markets. We believe their wisdom and guidance is invaluable to our audiences,” said Morgan Fogg, Vice President of Community & Events at SRAX.

Marijuana Company Of America Inc, Item 9 Labs, Delic Corp., Can B Corp., and Pressure Biosciences, Inc. are the sponsors of this exciting event.

About SRAX
SRAX (NASDAQ: SRAX) is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX, visit srax.com and mysequire.com.

Cautionary Statement Regarding Forward-Looking Information:

This news release contains "forward-looking statements" made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "seek" or "will." Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in our business, and our need for future capital. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in SRAX's periodic reports filed with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2020, its Quarterly Reports on Form 10-Q as well as and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.

Contact
Bri Kelvin
Investors@srax.com